newsfilter
← Latest News
Business Wire·

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates

  • Zura Bio reported financial results for the third quarter ended September 30, 2025, while advancing two Phase 2 clinical trials for tibulizumab in hidradenitis suppurativa (TibuSHIELD) & systemic sclerosis (TibuSURE).
  • Topline data for the TibuSHIELD trial is expected in the third quarter of 2026, while data for the TibuSURE trial is projected for the fourth quarter of 2026.
  • The company held $139.0 million in cash & cash equivalents as of September 30, 2025, which is anticipated to fund operations through 2027.
  • Research & development expenses increased to $11.9 million in Q3 2025 from $6.0 million in the prior year period due to progress in tibulizumab trials.
  • General & administrative expenses decreased to $7.6 million in Q3 2025 from $13.3 million in the prior year period, primarily driven by a one-time non-cash share-based compensation expense in Q3 2024.
  • The company reported a net loss of $20.0 million ($0.21 per share) for Q3 2025, compared to a loss of $22.9 million ($0.26 per share) for the same period in 2024.
  • Tibulizumab is a bispecific antibody designed to neutralize IL-17A & BAFF, with additional candidates crebankitug (ZB-168) & torudokimab (ZB-880) having completed Phase 1/1b studies.